About Us

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate, is initially being developed as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.


  • Wilson Therapeutics AB (publ)
    Västra Trädgårdsgatan 15 SE-111 53 Stockholm
    +46 8 796 00 00
  • Anders Martin-Löf, CFO
    +46 8 796 00 00
  • Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top